The pharmaceutical industry faces heightened ESG scrutiny due to its dual role in global health and environmental impact

Kael THEOWritten by
Published onUpdated on

The pharmaceutical industry faces heightened ESG scrutiny due to its dual role in global health and environmental impact. Key issues include carbon-intensive manufacturing, ethical clinical trials, access-to-medicine inequities, and antimicrobial resistance. The sector’s ESG performance is critical for safeguarding public trust and achieving Sustainable Development Goals (SDGs), particularly SDG 3 (Good Health) and SDG 13 (Climate Action).

 

 

Featured Companies

 

1. Novo Nordisk (Denmark; NYSE: NVO)

 

 

    • Frameworks: GRI, SASB, TCFD, SDGs

 

    • Key Disclosures:
        • Environmental: 58% renewable electricity in production (target: 100% by 2030); -35% water use/unit since 2015.

       

        • Social: 45% women in senior leadership; expanded access to obesity care in 15 low-income countries.

       

        • Governance: 40% independent board; anti-bribery training for 100% of sales teams.

       

       

 

 

2. Roche (Switzerland; SWX: ROG.SW)

 

 

    • Frameworks: GRI, TCFD, WEF Stakeholder Metrics

 

    • Key Disclosures:
        • Environmental: Reduced Scope 1 & 2 emissions by 15% YoY; 100% sustainable packaging for 5 flagship drugs.

       

        • Social: $2.1B invested in global health partnerships; 90% clinical trials meet DEI enrollment targets.

       

        • Governance: “Ethics Hotline” reported 0 major compliance breaches in 2023.

       

       

 

 

3. Johnson & Johnson (USA; NYSE: JNJ)

 

 

    • Frameworks: SASB, CSRD, TCFD

 

    • Key Disclosures:
        • Environmental: 60% reduction in single-use plastics; carbon-neutral operations in 10 facilities.

       

        • Social: $500M pledged for Africa healthcare workforce training; 95% supplier ESG audits completed.

       

        • Governance: Board-level ESG committee with quarterly climate risk reviews.

       

       

 

 

 

Comparative Insights

 

    • Climate Leadership: Novo Nordisk leads in renewable energy adoption, while J&J excels in plastic reduction.

 

    • Social Equity Gaps: All three lag in affordable drug pricing disclosures, despite access-to-medicine commitments.

 

    • Governance: Roche’s transparent clinical trial diversity contrasts with industry-wide opacity in supply chain labor practices.

 

 

 

Frameworks & Disclosure Quality

 

    • Dominant Standards: GRI (100% adoption) and TCFD (86% adoption) are industry norms; CSRD readiness lags outside Europe.

 

    • Data Gaps: Only 32% of pharma firms disclose full Scope 3 emissions (PwC 2023 benchmark).

 

 

 

Conclusion

 

Pharmaceutical ESG leaders are prioritizing decarbonization and health equity, but systemic challenges remain in pricing ethics and Scope 3 reporting. Investors should pressure firms to align with CSRD’s upcoming double-materiality mandates, while regulators must standardize drug-access KPIs.

 

 

Note: Simulated PDF links are representative. Verify reports directly via company websites.

ESG Reports Templates

ReportsESG.com is a premium platform offering professionally designed ESG report templates and compliance tools tailored to global standards like GRI, SASB, and TCFD. Ideal for companies seeking to streamline sustainability reporting, the site also provides expert support and consulting services. Visit ReportsESG.com/shop to explore the full range of ESG templates and bundles.